 | Up a level |
Journal Article
Broeckelmann, P. J., Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Seal, B., Dalal, M. R. and Illidge, T. (2016). BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY. Haematologica, 101. S. 50 - 52. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eichenauer, D. A., Aleman, B. M. P., Andre, M., Federico, M., Hutchings, M., Illidge, T., Engert, A. and Ladetto, M. (2018). Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 29. S. 19 - 30. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Eichenauer, D. A., Engert, A., Andre, M., Federico, M., Illidge, T., Hutchings, M. and Ladetto, M. (2014). Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 25. S. 70 - 76. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Sea, B., Dalal, M. R., Broeckelmann, P. J. and Illidge, T. (2016). REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION. Haematologica, 101. S. 51 - 52. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zagadailov, E. A., Corman, S., Hagan, M., Chirikov, V., Johnson, C., Macahilig, C., Seal, B., Dalal, M. R., Illidge, T. and Broeckelmann, P. J. (2016). RISK FACTORS FOR RELAPSE IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANT: A REAL-WORLD ANALYSIS IN GERMANY AND THE UNITED KINGDOM. Haematologica, 101. S. 51 - 53. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078